Hardman & Co’s analysts have direct experience of uncovering accounting frauds. In this article, Steve Clapham outlines why we might see a surge in them over the next few years. He is engaged by institutions to teach their fund managers and analysts how to identify risks brought about by such frauds. Hardman & Co is pleased to offer this service to private investors.

01 Aug 2018
The Monthly
Time Finance plc (TIME:LON), 56.0 | Allergy Therapeutics plc (AGY:LON), 6.9 | Alliance Pharma plc (APH:LON), 64.6 | Arbuthnot Banking Group PLC (ARBB:LON), 908 | Avacta Group PLC (AVCT:LON), 33.5 | Burford Capital Limited (BUR:LON), 1,016 | City of London Investment Group PLC (CLIG:LON), 355 | TheraCryf PLC (TCF:LON), 0.2 | Genedrive Plc (GDR:LON), 1.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Primary Health Properties PLC (PHP:LON), 101 | R.E.A. Holdings plc (RE:LON), 72.2 | Scancell Holdings Plc (SCLP:LON), 10.0 | Surface Transforms PLC (SCE:LON), 0.5 | Tissue Regenix Group plc (TRX:LON), 32.5 | Titon Holdings Plc (TON:LON), 70.0 | Warpaint London PLC (W7L:LON), 412 | Oxford BioMedica plc (OXB:LON), 308 | ValiRx PLC (VAL:LON), 0.6

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly
Time Finance plc (TIME:LON), 56.0 | Allergy Therapeutics plc (AGY:LON), 6.9 | Alliance Pharma plc (APH:LON), 64.6 | Arbuthnot Banking Group PLC (ARBB:LON), 908 | Avacta Group PLC (AVCT:LON), 33.5 | Burford Capital Limited (BUR:LON), 1,016 | City of London Investment Group PLC (CLIG:LON), 355 | TheraCryf PLC (TCF:LON), 0.2 | Genedrive Plc (GDR:LON), 1.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Primary Health Properties PLC (PHP:LON), 101 | R.E.A. Holdings plc (RE:LON), 72.2 | Scancell Holdings Plc (SCLP:LON), 10.0 | Surface Transforms PLC (SCE:LON), 0.5 | Tissue Regenix Group plc (TRX:LON), 32.5 | Titon Holdings Plc (TON:LON), 70.0 | Warpaint London PLC (W7L:LON), 412 | Oxford BioMedica plc (OXB:LON), 308 | ValiRx PLC (VAL:LON), 0.6
- Published:
01 Aug 2018 -
Author:
Steve Clapham -
Pages:
40 -
Hardman & Co’s analysts have direct experience of uncovering accounting frauds. In this article, Steve Clapham outlines why we might see a surge in them over the next few years. He is engaged by institutions to teach their fund managers and analysts how to identify risks brought about by such frauds. Hardman & Co is pleased to offer this service to private investors.